The liver imaging and reporting data system treatment response algorithm (LIRADS TRA) for CT and MRI has been used to predict residual viable tumor after treatment with yttrium-90 (Y-90). This single-center cohort of 20 patients were reviewed using the LIRADS TRA assessing residual viable tumor following Y-90 therapy. Pathology of subsequent liver explants was the reference standard. The LIRADS TRA predicted positive treatment effect (nonviable): NPV 82.4% (95% CI 0.47-1.55), accuracy 75% (72.0-89.4). The results of this preliminary study will need further validation in a larger, similar, pathologic-confirmed cohort.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords